Cyclerion Therapeutics faces a precarious financial outlook characterized by a lack of sustainable revenue, as evidenced by the 100% revenue contraction in 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | -$0.41+94.2% vs -$7.10 | — vs $2M |
Q2 2026 May 12, 2026 | -$0.76+95.6% vs -$17.20 | — vs — |
Q2 2026 Mar 30, 2026 | -$0.19+50.0% vs -$0.38 | $100,000+0.0% vs $100,000 |
Q2 2026 Mar 25, 2026 | -$0.38+0.0% vs -$0.38 | $100,000+0.0% vs $100,000 |
Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer's patients anticipated by year-end 2027 or first quarter of 2028
Benchmark KRSA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Korsana Biosciences, Inc. (KRSA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $31.05 | $18.86M | -2.81 | 3.7% | -353% | -87.96% | — | |
| $12.73 | $2.95B | 15.76 | 19.63% | 35.14% | 42.56% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $0.16 | $11.56K | -0.00 | — | — | -222.32% | — | |
| $7.97 | $417.26M | -17.11 | -92.84% | -45.43% | -8.34% | — | |
| $3.90 | $1.25B | -16.69 | 22.23% | -18.1% | — | — |
Korsana Biosciences, Inc. (KRSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Korsana Biosciences, Inc. (KRSA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 5, 2026·SEC
Sep 11, 2026·SEC
Aug 27, 2026·SEC
Get notified when KRSA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Korsana Biosciences, Inc. (KRSA) stock FAQ — growth, dividends, profitability & financials explained
Korsana Biosciences, Inc. (KRSA) reported $1.9M in revenue over the trailing twelve months. Revenue was $2.1M in fiscal year 2025.
Korsana Biosciences, Inc. (KRSA) revenue fell by 12.6% over the trailing twelve months, compared with the twelve months before.
No. Korsana Biosciences, Inc. (KRSA) reported a net loss of $6.7M over the trailing twelve months.
Korsana Biosciences, Inc. (KRSA) had a return on equity (ROE) of -88.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Korsana Biosciences, Inc. (KRSA) had negative free cash flow of $4.5M over the trailing twelve months.
